Most neoplasms do not induce antitumor immune responses
Introduction
Cancer cells including melanoma cells form weakly immunogenic, tumor associated antigens (TAAs). [1] [2] [3] [4] Under approriate circumstances, they can be recognized by cytotoxic T lymphocytes (CTLs) of the tumor-bearing animal, or cancer patient. TAAs are the products of dysregulated or mutant genes in the neoplastic cells that differ from the homologous genes in non-neoplastic cells of the same individual. Like other neoplasms, melanoma cells form TAAs. The products of genes that specify TAAs expressed by melanoma cells, such as BAGE, GAGE-1, MAGE-1, MAGE-2, MAGE-3, gp100 and tyrosinase, among others, have been identified as the targets of CTLs. [5] [6] [7] [8] [9] [10] [11] [12] [13] It is likely that these TAAs are only several representations of an undefined, and possibly large number of TAAs expressed by different cells that comprise the malignant cell population. Genetic instability is a characteristic phenotype of cancer cells.
fibroblasts survived significantly longer than mice in various control groups. To investigate the contribution of MHC determinants expressed by the transfected cells to their immunogenic properties, we compared the antimelanoma responses in mice immunized with transfected cells that expressed allogeneic or syngeneic class I determinants. The results indicated that the immunogenic properties of the DNA-transfected cells were enhanced if the cells expressed allogeneic MHC determinants. The antimelanoma responses of greatest magnitude, however, mediated predominantly by CD8

+ T cells, were in mice immunized with transfected fibroblasts that expressed both syngeneic and allogeneic class I determinants.
Gene Therapy (2002) 9, 1163-1172. doi:10.1038/sj.gt.3301765 neoplasm are not detected in tumor-bearing animals, or patients. A number of novel strategies have been investigated to augment the immunogenic properties of 'weak' TAAs expressed by cancer cells. The hope is that an effective vaccination strategy can be developed that might be used in the treatment of cancer patients. 19 In prior studies, we found that CD8
+ CTL-mediated anti-B16 melanoma immune responses were generated in mice immunized with LM cells, a mouse fibroblast cell line, that had been transfected with DNA from the melanoma cells. [20] [21] [22] The immunity was sufficient to deter tumor progression, and to prolong survival, although in most instances the animals eventually succumbed from recurrent growth of the neoplasm. We hypothesized that an array of undefined genes encoding weakly immunogenic TAAs formed by the proliferating melanoma cells were expressed in a highly immunogenic form by the transfected cells. The transfected cells expressed TAAs of the DNA-donor, since the antimelanoma responses in the immunized mice were specific for melanoma and not for other types of neoplasms.
Transfer of DNA from the neoplasm into a highly immunogenic cell line for the purpose of developing a tumor vaccine was an extension of established studies. [23] [24] [25] [26] [27] [28] [29] [30] [31] These studies indicated that transfection of genomic DNA from one cell type to another resulted in integration of the exogenous DNA and stable expression of the trans-ferred genes. This was the case for genes specifying missing enzymes, as well as for genes specifying membraneassociated determinants.
Here, we investigated the development of antimelanoma immune responses in C57BL/6 mice (H-2 b ) immunized with fibroblast cell lines transfected with DNA from B16 cells, a highly aggressive melanoma cell line derived from a tumor that arose in a C57BL/6 mouse. The fibroblast cell lines were selected because they expressed syngeneic (H-2 b ) or allogeneic (H-2 k ) MHC class I determinants, along with the costimulatory molecule B7.1, enabling them to act as antigen presenting cells. 32, 33 Before DNA transfer, the fibroblasts were modified to secrete IL-2, to further augment their immunogenic properties. 34 The immunogenic properties of the transfected cells were then compared in C57BL/6 mice with melanoma. The results indicated that the expression of allogeneic MHC determinants by the transfected cells was an essential component of the vaccine. Mice immunized with transfected fibroblasts that expressed allogeneic class I determinants survived significantly longer than mice immunized with transfected fibroblasts that expressed syngeneic determinants. The strongest antimelanoma responses, however, were in mice immunized with viable transfected fibroblasts that expressed both syngeneic and allogeneic class I determinants. . Melanoma vaccines were prepared by transfection of the cells with DNA from B16 melanoma cells, syngeneic in C57BL/6 mice. Before testing the immunotherapeutic properties of the vaccines, an immunofluorescence assay was used to determine if the cells selected as recipients of DNA from the melanoma cells expressed MHC class I determinants. Quantitative immunofluorescent measurements using FITC-conjugated mAbs for H-2K k or H-2K b class I determinants were used in the analysis. As indicated (Figure 1 ), the mean fluorescence index (MFI) of LM cells incubated with FITC mAbs for H-2K k determinants was significantly higher than the MFI of LM cells incubated with FITC-conjugated mAbs for H-2K b determinants, or with FITC-conjugated IgG2a isotype serum. In an analogous manner, the MFI of BLK cells stained with FITC-conjugated mAbs for H-2K b determinants was significantly higher than the MFI of BLK cells stained with FITC-conjugated mAbs for H-2K k determinants, or with the FITCconjugated isotype serum. Thus, the cells used as recipients of DNA from the melanoma cells expressed class I determinants that were characteristic of the strain of mice from which the cells were derived. 
Results
LM and BLK cells, mouse fibroblast cell lines, express MHC class I-determinants constitutively
LM and BLK cells expressed B7.1, a co stimulatory molecule required for T cell activation
Modification of LM cells and BLK cells to secrete IL-2
Local delivery of IL-2 mobilizes immune cells to the site of injection of the vaccine and stimulates T cell proliferation. 34 Before transfection with DNA from the melanoma cells, LM cells and BLK cells were modified to secrete IL-2. A replication-defective retrovirus was used for this purpose.
The retroviral vector (pZipNeoSV-IL-2) specified the gene for human IL-2, along with a gene (neo r ) that conferred resistance to the neomycin analog, G418. 35 For use as a control, a vector (pZipNeoSV(X)) that specified the neo r gene, but lacked the IL-2 gene was substituted for pZipNeoSV-IL-2. LM cells and BLK cells were trans- duced with pZipNeoSV-IL-2 or pZipNeoSV(X). After selection in growth medium containing sufficient quantities (400 g/ml) of G418 to kill 100% of the non-transduced cells, the surviving colonies were pooled and maintained as modified cell lines. A biological assay of the cell culture supernatants of the G418-resistant LM or BLK cells transduced with pZipNeoSV-IL-2 (LM-IL-2 and BLK-IL-2 cells, respectively) indicated that 1 × 10 6 cells formed approximately 100 units IL-2 in 48 h, as determined by the capacity of the culture supernatants to sustain the growth of IL-2-dependent CTLL-2 cells (Table 1 b cells with DNA from B16 melanoma cells (described below) did not significantly affect the amount of IL-2 secreted by the cells. Every third passage, the cells were maintained in medium containing 400 g/ml G418. Under these conditions, equivalent amounts of IL-2 were detected in the culture supernatants of each of the modified cell lines for more than 6 months of continuous culture (these data are not presented).
Gene Therapy 1 × 10 6 of the respective cell types were maintained under standard cell culture conditions in 10 ml growth medium for 48 h. Afterwards, aliquots of the cell culture supernatants were assayed for the presence of IL-2, as described in the Materials and methods section. Each value represents the mean of triplicate determinations. 1 Transduced with pZipNeoSV(X), followed by selection in growth medium containing 400 g/ml G418. 2 Transduced with pZipNeoSV-IL-2, followed by selection in growth medium containing 400 g/ml G418. 
Modification of LM-IL-2 cells to express H-2K
b class I determinants The introduction of allogeneic MHC determinants into weakly antigenic tumor cells augments the cells' immunogenic properties. [36] [37] [38] [39] [40] The foreign MHC determinants act as an immune adjuvant. Conceivably, the immunogenic properties of the cells used as recipients of DNA from the melanoma cells would be enhanced if the cells expressed both allogeneic and syngeneic MHCdeterminants. Syngeneic class I determinants could aid in the induction of the antimelanoma response by providing a restriction element for direct antigen presentation to CTLs of the host. To investigate this question, the gene for H-2K b was introduced into LM-IL-2 fibroblasts before the cells were transfected with DNA from B16 melanoma cells. A plasmid (pBR327H-2K b ) was used for this purpose. In the experiment, LM-IL-2 cells were cotransfected with pBR327H-2K b and a vector (pBabePuro) that conferred resistance to puromycin, used for selection. A 10:1 ratio of pBR327H-2K b to pBabePuro was used to increase the likelihood that the cells that were converted to puromycin-resistance took up the vector specifying H-2K b determinants as well. After transfection, the cells (LM-IL-2K b ) were selected in growth medium containing sufficient quantities of puromycin (3 g/ml) to kill 100% of non-transfected LM-IL-2 cells. The colonies of puromycin-resistant cells were pooled and maintained as a cell line.
Quantitative immunofluorescent staining using FITCconjugated specific mAb was used to determine if the puromycin-resistant, transfected cells expressed H-2K significantly different than the MFI of cells tested shortly after transfection.
Cellular anti melanoma responses were generated in C57BL/6 mice immunized with LM-IL-2K b cells transfected with DNA from B16 melanoma cells
The vaccine was prepared by co transfection of DNA from B16 melanoma cells, along with a plasmid specifying resistance to hygromycin into modified LM fibroblasts ( Figure 4 ). After selection, the hygromycin-resistant cells were pooled and maintain as a cell line. The transfected cells were then tested in C57BL/6 mice, syngeneic with the melanoma cells. Naive mice received three s.c. and i.p. injections of viable transfected cells at weekly Cr-release) toward B16 melanoma cells were detected in the group of mice immunized with LM-IL-2/B16 cells, the transfected fibroblasts that expressed allogeneic MHC-determinants alone. Immunizations with BLK-IL-2/B16 cells, the transfected cells that expressed syngeneic MHC determinants alone, failed to result in the generation of antimelanoma responses.
As controls, naive C57BL/6 mice were immunized according to the same schedule with equivalent numbers of (non-DNA-transfected) LM-IL-2 cells, or with equivalent numbers of (non-DNA-transfected) BLK-IL-2 cells, and the cytotoxic responses toward B16 melanoma cells were determined. The results (Table 2) indicated that antimelanoma responses failed to develop in the mice immunized with the allogeneic or syngeneic IL-2-secreting fibroblasts that had not been transfected with DNA from the melanoma cells, indicating that DNA transfer was an essential component of the vaccine. As an additional control, naive C57BL/6 mice were immunized with non-IL-2-secreting, non-DNA-transfected LM or BLK cells, and the cytotoxic responses toward B16 cells were determined. As indicated (Table 2) , cytotoxic immune responses toward the melanoma cells were not detected in these mice. As expected, cytotoxic responses toward the allogeneic (LM) fibroblasts were present in C57BL/6 mice immunized with LM cells, LM-IL-2 cells or LM-IL-2/B16 cells (Table 2) .
Thus, cytotoxic responses toward the melanoma cells were found in the group of mice immunized with IL-2-secreting, DNA-transfected fibroblasts that expressed allogeneic MHC determinants.
The same protocol was followed to measure the antimelanoma response in C57BL/6 mice immunized with transfected cells that expressed both syngeneic (H-2 (Table 2) indicated that the highest (P Ͻ 0.01) antimelanoma responses were in the group of mice immunized with the vaccine that combined both syngeneic and allogeneic MHC determinants. Lesser responses were in mice immunized with transfected cells that expressed allogeneic MHC determinants alone. The response in mice immunized with transfected cells that expressed syngeneic determinants alone was significantly (P Ͻ 0.01) less than that found in mice immunized with the vaccines that included allogeneic MHC determinants.
The contribution of NK/LAK cells to the antimelanoma responses was determined by preincubation of spleen cells from the immunized mice with asialo GM1 mAbs before the cytotoxicity determinations toward B16 cells were performed. As indicated (Table 2) , pretreatment of the cells with asialo GM1 mAbs reduced, but did not eliminate the cytotoxic responses toward B16 cells. Cytotoxic responses toward (allogeneic) LM cells were detected in each instance.
Survival of C57BL/6 mice injected with B16 melanoma cells and IL-2-secreting fibroblasts transfected with DNA from B16 cells
Our previous studies [20] [21] [22] were carried out in tumor-bearing mice immunized with transfected fibroblasts modified for IL-2-secretion that expressed allogeneic MHC b cells, or with growth medium. The mice received two subsequent s.c. injections of each cell type at weekly intervals. One week after the last injection, the mice were killed and pooled spleen cell suspensions from mice in each group were tested in a standard 51 Cr-release assay for the presence of cytotoxic responses toward B16 or LM cells, as described in the Materials and methods. In some instances, 10 l asialo GM-1 antibodies were added to the spleen cell suspensions before the 51 Cr-release assays were performed. The experiment was performed three times with equivalent results. There were three mice in each group. determinants alone. Here, we investigated the relative immunotherapeutic properties C57BL/6 mice immunized with syngeneic or allogeneic IL-2-secreting fibroblasts transfected with DNA from the melanoma cells. Naive mice were injected s.c. with a mixture of 5 × 10 To determine if immunization with IL-2-secreting fibroblasts that expressed both allogeneic, as well as syngeneic class I determinants had additional therapeutic benefits, naive C57BL/6 mice were injected according to Gene Therapy 
B16 cells alone. As controls, naive C57BL/6 mice were injected according to the same protocol with equivalent numbers of B16 cells and LM-IL-2/B16 cells, with B16 cells and BLK-IL-2/B16 cells, or with B16 cells and growth media. Survival of mice injected with B16 cells and LM-IL-2K b /B16 cells, relative to the survival of mice in each of the other groups, P Ͻ 0.001. Survival of mice injected with B16 cells and BLK-IL-2/B16 cells and mice injected with B16 cells alone, not significant. Survival of mice injected with B16 cells and LM-IL-2/B16 cells, and mice injected with B16 cells alone, P Ͻ 0.01. --ᮀ --Media; --᭺ --LM-IL-2/B16; ----BLK-IL-2/B16; --̆--LM-IL-2K
b /B16. the same protocol with equivalent numbers of B16 melanoma cells and IL-2-secreting fibroblasts that expressed both syngeneic and allogeneic class I MHC-determinants (LM-IL-2K b /B16 cells). The results ( Figure 5 ) indicated that the survival of mice injected with B16 cells and the vaccine that combined both syngeneic and allogeneic determinants exceeded that of any of the other groups. Two of the mice in this group appeared to have rejected the melanoma cells and survived indefinitely, more than 6 months, without evidence of disease.
Discussion
Under ordinary circumstances, progressively growing neoplasms do not provoke antitumor immune responses that can control tumor growth, even if the cells express unique TAAs. The TAAs are insufficiently immunogenic. Effective antitumor immune responses are not usually found in tumor-bearing animals, or patients. A variety of strategies have been used to augment the immunogenic properties of weakly immunogenic TAAs expressed by cancer cells. [41] [42] [43] [44] [45] [46] [47] The expectation is that a vaccine that successfully induces an antitumor immune response will be of benefit to cancer patients. Since objective evidence of tumor regression has been observed in tumor-bearing animals, and patients treated solely by immunization with various forms of tumor vaccines, this type of therapy could have an important role in the overall management of patients with malignant disease.
In prior studies, we detected robust, antitumor immune responses in tumor-bearing mice immunized with allogeneic LM mouse fibroblasts transfected with DNA from mouse melanoma or mouse breast carcinoma cells. 35, 36 Immunizations with fibroblasts transfected with DNA from non-neoplastic cells, or with non-transfected fibroblasts failed to generate significant antitumor immune responses. Since the immunity was mediated predominantly by CD8 + CTLs, and was specific for the type of tumor from which the DNA was obtained, we concluded that the transfected cells expressed undefined, weakly immunogenic TAAs that characterized the population of malignant cells.
A vaccine prepared by transfer of DNA from a neoplasm into a highly immunogenic cell line has certain important advantages. The primary advantage is that the cells used as recipients of the DNA can be selected for desirable properties, for example, for rapid and continuous proliferation in culture and for the expression of costimulatory molecules required for antigen presentation, allogeneic and at least one syngeneic class I MHC determinant. Continuous proliferation of the cells that take up and incorporate DNA from the tumor enables a vaccine to be prepared from only small quantities of DNA, as the transferred DNA is replicated as the cells divide. In the experiments reported here, the fibroblasts were routinely transfected with 100 g of DNA from the melanoma cells. The lower limit of DNA required to prepare an effective vaccine has not determined, and it is likely that lesser amounts of DNA would be sufficient. Conceivably, a needle biopsy of the patient's tumor might provide enough DNA for this purpose. Since the fibroblasts that take up the DNA are capable of indefinite proliferation in vitro, the transfected cells were allowed to proliferate until sufficient numbers were obtained for repeated immunizations.
The fibroblasts used as recipients of DNA from the tumor were modified before transfection to augment their immunogenic properties. We introduced the gene for IL-2 into the cells. Conceivably, the immunogenic properties of the cells could be further enhanced if they were modified to form more than one immune-augmenting cytokine with synergistic immune-enhancing properties, as for example, IL-2 and interferon gamma. 50 As recipients of DNA from the melanoma, we selected mouse fibroblast cell lines that expressed B7.1 and defined MHC class I determinants. After modification to secrete IL-2, the cells were transfected with sheared, unfractionated DNA from B16 cells, a highly aggressive mouse melanoma originating in C57BL/6 mice ( Figure  4) . After a period of growth in vitro, the cell number was expanded and the transfected cells were tested for their immunotherapeutic properties against the melanoma in C57BL/6 mice, highly susceptible to growth of the neoplasm. The results indicated that mice injected with melanoma cells and the allogeneic transfected cells survived significantly longer than mice in various control groups, although in most instances they succumbed to progressive tumor growth.
The resistance to tumor growth in mice injected with the allogeneic-based vaccine was reflected in the results of cytotoxicity studies performed in vitro. The specific In addition to MHC determinants, the fibroblasts selected for transfection also expressed B7.1, a costimulatory molecule required for T cell activation. Since B16 cells, like other types of tumor cells, have diminished or absent MHC class I molecules, and do not express costimulatory molecules, the expression of both MHC determinants and B7.1 molecules by the DNA-recipient cells further enhanced the development of the antitumor immune response. 48 Transfer of DNA from the neoplasm into a selected cell line avoids the need to establish a cell line from the primary neoplasm. A tumor cell line is required if stable transfection of genes specifying cytokines, allogeneic MHC determinants, costimulatory molecules or genes for other immune-augmenting properties are to be introduced into autologous tumor cells. The establishment of tumor cell lines is often unsuccessful, and, in those instances in which a cell line of the primary tumor can be established, there is no assurance that the cells that are capable of proliferating in vitro are representative of the tumor cell population as a whole.
Transfection of DNA from the tumor into a highly immunogenic, selected cell line also avoids the need to define the 'clinically relevant' tumor antigen, that is, immunity to tumor antigens that lead to tumor rejection. While new TAAs are being identified, which TAA to use for immunization requires a process of 'antigen discovery'. With few exceptions, clinically relevant tumor antigens have not been identified. The heterogeneity of antigen expression in the tumor population complicates the choice and there is a danger that some tumor cells among the malignant cell population may not express the antigen chosen for therapy. For example, de Vries et al 49 found that expression of known tumor antigens such as gp100 and tyrosinase was variable in different melanoma lesions within the same patient, implying that the entire repertoire of tumor antigens even within the same tumor cell population may be broad. Thus, a vaccine strategy that stimulates an immune response to multiple tumor antigens expressed by the malignant cell population may be more successful in eliminating a larger number of tumor cells than a strategy that induces immune responses to a single antigen alone. 50 Whether or not the immunity in mice injected with the DNA-transfected allogeneic cells was local or systemic was not determined. However, the failure of non-DNAtransfected cells to induce an antimelanoma response is consistent with the development of a systemic response. Prior studies indicated that the antimelanoma immunity in mice immunized with transfected fibroblasts was both systemic and long term. The mice were resistant when rechallenged more than 3 months after immunization. 48 
Materials and methods
Experimental animals and cell lines
Eight to 10-week-old pathogen-free C57BL/6 (H-2 b ) female mice were from the Jackson Laboratory (Bar Harbor, ME, USA). The mice were maintained according to NIH Guidelines for the Care and Use of Laboratory Animals. They were 10 to 14 weeks old when used in the experiments.
B16 cells, a melanoma cell line, were obtained from I Fidler (MD Anderson Cancer Center, Houston, TX, USA). The cells were maintained by serial passage in histocompatible C57BL/6 mice, or at 37°C in a humidified 7% CO 2 /air atmosphere in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma, St Louis, MO, USA) and antibiotics (Gibco BRL) (growth medium). LM cells, a fibroblast cell line of C3H mouse origin (H-2 k ) were from the American Type Culture Collection (Rockville, MD, USA). Like B16 cells, LM cells were maintained at 37°C in a humidified 7% CO 2 /air atmosphere in growth medium. BLK-SV (BLK), a fibroblast cell line, WRI9M.I cells, a macrophage cell line (both of C57BL/6 mouse origin) were from the American Type Culture Collection. The cells were maintained in growth medium at 37°C in a humidified 7% CO 2 /air atmosphere.
Modification of LM and BLK fibroblasts to secrete IL-2
LM and BLK fibroblasts were modified for IL-2 secretion by transduction with the retroviral vector pZipNeoSV-IL-2 (from MKL Collins, University College, London, UK). The vector, packaged in GP+env AM 12 cells (from A Bank, Columbia University, New York, NY, USA), included a human IL-2 cDNA and a neo r gene, both under control of the Moloney leukemia virus long terminal repeat. The neo r gene conferred resistance to the aminoglycoside antibiotic G418 (Gibco BRL). For use as a control, LM fibroblasts were transduced with the retroviral vector pZipNeoSV(X) (from MKL Collins), also packaged in GP+env AM 12 cells (LM-ZipNeo cells). pZipNeoSV(X) specified the neo r gene, but lacked the gene for IL-2.
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Virus-containing supernatants of GP+env AM 12 cells transfected with pZipNeoSVIL-2, or pZipNeoSV(X), were added to LM or BLK cells, followed by overnight incubation at 37°C in growth medium containing polybrene (Sigma; 5 mg/ml, final concentration). The cells were maintained for 14 days in growth medium containing 400 g/mI G418 (Gibco BRL). One hundred percent of nontransduced LM or non-transduced BLK cells died in the G418-containing medium during this period. Colonies of cells proliferating in the selection medium were pooled and maintained as modified cell lines for later use in the experiments. A standard curve was generated by adding varying amounts of recombinant human IL-2 (Gibco BRL) to an equivalent number of CTLL-2 cells. Afterward, the cells were collected on to glass fiber filters (Whittaker MA Products, Walkerville, MD, USA) using a PhD multiple harvester (Microbiological Associates, Bethesda, MD, USA). After washing with ethanol (95%), the radioactivity in the insoluble fraction was measured in a liquid scintillation spectrometer (Packard Instrument, Downers Grove, IL, USA). One unit of IL-2 resulted in half maximal proliferation of CTLL-2 cells under these conditions. Every third passage, the transduced cells were cultured in growth medium containing 400 g/ml G418. o C in growth medium under standard cell culture conditions. After incubation for 48 h, the cell cultures were divided and replated in growth medium supplemented with 3.0 g/ml puromycin (Sigma, St Louis, MO, USA), followed by incubation at 37°C for 7 additional days. The surviving colonies were pooled and maintained as a cell line for later testing by immunofluorescence for the expression of H-2K b determinants. One hundred percent of non-transfected LM-IL-2 cells maintained in growth medium containing puromycin died during the 7-day period of incubation.
Modification of LM-IL-2 cells to express H-2K
Immunofluorescent staining and cytofluorometric measurements
The expression of H-2 determinants by the modified cells was determined by quantitative immunofluorescence. The measurements were performed in an Epic V flow cytofluorograph (Coulter Electronics, Hialeah, FL, USA) equipped with a multiparameter data acquisition and display system (MDADS). For the analysis, a single cell suspension was prepared from plastic-adherent monolayer cultures disassociated with 0.1 mM EDTA in PBS. The cells in suspension were washed with PBS containing 0.2% sodium azide and 0.5% FBS. Afterward, FITC-conjugated H-2K b or H-2K k mAbs (Pharmingen) or FITC-conjugated IgG2a isotype serum (DAKO) was added to the cells, followed by incubation at 4°C for 1 h. After incubation, the cells were washed with PBS containing 0.5% FBS and 0.2% sodium azide. One-parameter fluorescence histograms were generated by analyzing at least 1 × 10 4 cells. Background staining was determined by substituting cells stained with FITC-conjugated mouse IgG2a alone for cells stained with the specific antibodies. The 15% of cells that stained with the highest intensity was separated into 15 ml conical tubes (Falcon) containing DMEM supplemented with 50% FBS. Immediately afterwards, the cells were centrifuged at low speed and resuspended in growth medium in plastic tissue culture plates (Falcon), followed by incubation at 37°C in a humidified 7% CO 2 /air atmosphere. In addition, B16 cells, LM cells, and WRI9M.I cells were tested for the expression of B7-1, B7-2 and ICAM-1 determinants. The same procedure was followed except that FITC-conjugated-B7-1 mAbs, FITC-conjugated-B7-2 mAbs or FITC-conjugated ICAM-1 antibodies (all from Pharmingen) were substituted for the H-2 antibodies. As a control, aliquots of the cell suspensions were incubated with IgG2a isotype serum (DAKO). After three washes with PBS (pH 7.4), 1 × 10 4 cells were analyzed for fluorescent staining in the flow cytofluorograph.
Transfection of the modified fibroblast cell lines with genomic DNA from B16 melanoma cells
The fibroblast cell lines, used as recipients of DNA from B16 cells, were modified to secrete IL-2 and, in the case of LM-IL-2 cells, to express H-2K b -determinants. LM-IL-2, LM-IL-2K b and BLK-IL-2 cells were transfected with DNA from the melanoma cells, using the method described by Wigler et al, as described previously. 23 In brief, high molecular weight DNA from the melanoma cells was sheared by three passages through a 25-gauge needle. Afterwards, 100 g of the sheared DNA was mixed with 10 g pHyg (from L Lau, University of Illinois at Chicago), a plasmid that encoded the E. coli enzyme hygromycin B phosphotransferase gene, conferring resistance to hygromycin B, used for selection. The sheared DNA and pHyg were mixed with Lipofectin, according to the manufacturer's instructions (Gibco BRL) and the DNA/Lipofectin mixture was added to 1 × 10 7 cells, which had been divided into 10 100-mm plastic cell culture plates 24 h previously. Eighteen hours after the addition of the DNA/Lipofectin mixture to the cells, the growth medium was replaced with fresh growth medium containing sufficient quantities (500 g/ml; Boehringer Mannheim, Indianapolis, IN, USA) of hygromycin to kill 100% of the non-transfected cells. For use as a control, DNA from B16 cells was omitted and 1 g of pHyg alone mixed with Lipofectin was added to an equivalent number of the modified fibroblasts. In each instance, the cells were maintained for 14 days in growth medium containing 500 g/ml hygromycin B. None of the non-DNAtransfected cells maintained in the hygromycin-growth medium were viable by the end of this period. The remaining colonies (at least 2 × 10 4 ) were pooled and maintained as cell lines. A standard   51 Cr-release assay was used to detect the presence of spleen cells with cytotoxic activity toward B16 cells in mice immunized with the transfected cells. The spleen cell suspensions were prepared by forcing spleens from the mice through number 40-gauge stainless steel screens in approximately 5 ml of ice-cold growth medium. The cells were collected and overlaid on to Histopaque 1077 gradients (Sigma) and centrifuged (400 g) for 30 min at room temperature. The viability of the mononuclear cells collected from the gradients at this point was greater than 98%, as determined by trypan blue dye exclusion (0.4%). Cells of the same type used to immunize the mice were treated with mitomycin C (Sigma) (50 g/ml for 45 min at 37°C). After washing, they were co-incubated under standard cell culture conditions for 5 days with aliquots of the spleen cell suspensions. The incubation medium consisted of RPMI-1640 medium (Gibco BRL) supplemented with 100 U/ml human IL-2, 10% FBS, 5 × 10 Ϫ2 mmol 2-mercaptoethanol, 15 mmol HEPES, 0.5 mmol sodium pyruvate and penicillin/streptomycin (Gibco). The ratio of spleen cells to mitomycin-C-treated cells during the co-incubation was 30:1. At the end of the 5-day incubation period, the population that failed to adhere to the plastic cell culture flasks was collected and used as the source of effector cells for the cytotoxicity determinations.
Spleen cell-mediated cytotoxicity determinations
For the cytotoxicity assay, 5 × 10 6 B16 cells were labeled with 51 Cr during a 1-h incubation period at 37°C in growth medium containing 100 Ci Na Cr-labeled cells were incubated for 4 h at 37°C with the effector cell population. Afterwards, the culture supernatants were harvested, using a SKATRON cell harvester, and the quantity of isotope released was measured in a gamma counter (Beckman, Palo Alto, CA, USA).
The percent specific cytolysis was calculated as: Experimental 51 Cr release Ϫ spontaneous 51 Cr release/ maximum 51 Cr release Ϫ spontaneous 51 Cr release × 100. The spontaneous release of 51 Cr was less than 15% of the total release in each instance.
Statistical analyses
The Student's t test was used to determine the statistical differences between the various experimental and control groups. A P value less than 0.05 was considered significant.
